Ilaria Palagi

Ilaria Palagi

Auto-generated profile, based on publicly available information

Ilaria Palagi

Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2025 in Acta Biomaterialia
Verified
Journal Article
Open access
JVJohanna Vetter
Johanna Vetter
IPIlaria Palagi
Ilaria Palagi
AWAri Waisman
Ari Waisman
Andreas BlaeserAndreas Blaeser
Andreas Blaeser
The blood-brain barrier is a physiological barrier between the vascular system and the nervous system. Under healthy conditions, it restricts the passage of most biomolecules into the brain, making drug development exceedingly challenging. Conventional cell-based in vitro models provide valuable insights into certain features of the BBB. Nevertheless, these models often lack the three-dimensional structure and dynamic interactions of the surrounding microenvironment, which greatly influence cell functionality. Consequently, considerable efforts have been made to enhance in vitro models for drug development and disease research. Recently, microfluidic organ-on-a-chip systems have emerged as promising candidates to better mimic the dynamic nature of the BBB. This review provides a comprehensive overview of recent BBB-on-chip devices. The typical building blocks, chip designs, the perfusion infrastructure, and readouts used to characterize and evaluate BBB formation are presented, analyzed, and discussed in detail. STATEMENT OF SIGNIFICANCE: The blood-brain barrier (BBB) is a highly selective barrier that controls what can enter the brain. While it protects the brain from harmful substances, it also hinders the delivery of treatments for neurological diseases such as Alzheimer's and Parkinson's. Due to its complexity, studying the BBB in living organisms remains difficult. However, recent advances in "organ-on-a-chip" technology have allowed scientists to create small, engineered models that replicate the BBB. These models provide a powerful platform to study diseases and test potential drugs with greater accuracy than traditional methods. Organ-on-a-chip devices are designed to mimic the behavior of organs or tissues in the human body, offering a more realistic and controlled environment for research. This review highlights recent breakthroughs in BBB-on-a-chip technology, showing how these models enhance current research and have the potential to transform the way we study brain diseases and develop new drugs. By integrating biology and engineering, BBB-on-a-chip technology has the potential to transform neuroscience research, improve drug development, and enhance our understanding of brain disorders.

20 September 2024 in Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
ESEva Schramm
Eva Schramm
VBVanessa Becker
Vanessa Becker
IPIlaria Palagi
Ilaria Palagi
MMMelanie Müller
Melanie Müller
TRThomas Rösler
Thomas Rösler
AWAri Waisman
Ari Waisman
The deubiquitinating enzyme CYLD negatively regulates NF-κB signaling by removing activating ubiquitin chains from several members of the NF-κB pathway. Thereby, CYLD is critical for the maintenance and differentiation of various immune cells. Despite the importance of the NF-κB pathway in microglia regulation, the role of CYLD in microglia has not been investigated so far. In this study, we investigated whether CYLD in microglia can protect against neuroinflammation using a newly generated conditional mouse strain (Rosa26-Cyld-tdTomato) that allows cell type-specific CYLD overexpression. Here, we show that overexpression of CYLD in microglia did not alter microglia numbers or microglia morphology in different brain regions. Additionally, CYLD overexpression did not modify the microglial response to LPS-induced neuroinflammation or the disease severity in experimental autoimmune encephalomyelitis (EAE). Finally, also immune cell infiltration into the CNS during EAE and under steady state conditions remained unaffected by microglial CYLD overexpression. Our findings suggest that CYLD overexpression does not alter microglial function, and thus does not represent a viable therapeutic strategy in neuroinflammatory conditions. This study highlights the complexity of ubiquitin-mediated signaling in neuroinflammation and the need for cell-type-specific investigations. The Rosa26-Cyld-tdTomato mouse model offers a valuable tool for studying CYLD’s role across various tissues and cell types. Key messages: Novel mouse strain for cell type-specific overexpression of the deubiquitinating enzyme CYLD. CYLD overexpression in microglia did not alter microglia numbers or morphology in the steady state. CYLD overexpression in microglia did not protect mice from LPS-induced neuroinflammation or EAE. CYLD overexpression in microglia did not influence their gene expression during neuroinflammation.

27 February 2026 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
PDF file
NRNishada S. Ramphal
Nishada S. Ramphal
XLXinyuan Liu
Xinyuan Liu
IPIlaria Palagi
Ilaria Palagi
RJRebecca Jasser
Rebecca Jasser
AMAlma N. Mohebiany
Alma N. Mohebiany
AWAri Waisman
Ari Waisman
NIK (Map3k14) is a central regulator of noncanonical NF-κB signaling and immune homeostasis. Mutations in this kinase are linked to autoimmune disorders, including multiple sclerosis (MS). Both germline and T cell–specific deletion of NIK had been demonstrated previously to be associated with resistance to developing experimental autoimmune encephalomyelitis (EAE), an animal model for MS. In this study, we show that NIK expression by circulating myeloid cells is crucial for EAE development. Mechanistically, we found starkly reduced priming of neuroantigen-specific T cells in the absence of NIK in CX3CR1+ cells. This reduction was associated with dysregulated expression of genes involved in antigen presentation and cell migration, as well as decreased IL-23 production. Notably, T cells primed by NIK-deficient myeloid cells regained their ability to induce EAE when incubated with IL-23 before being transferred into RagKO mice. Our data underline the crucial role of NIK in enabling myeloid cells to function effectively as antigen-presenting cells.